The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma
Latest Information Update: 24 Nov 2022
At a glance
- Drugs CD 20 CAR-T cell therapy Shanghai Longyao Biotechnology (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Shanghai Longyao Biotechnology
Most Recent Events
- 26 Nov 2019 New trial record